Pipeline

BP1101

  1. Fully-personalized neoantigen vaccine, inducing immunity against antigens derived from cancer-specific genetic mutations (neoantigens)
図1

BP1101, a fully-personalized neoantigen vaccine, induces immunity against antigens derived from cancer-specific genetic mutations (neoantigens). Tumor mutational burden (neoantigen burden) correlates with the response rate in immune checkpoint therapy. This checkpoint antibody is considered to enhance the antitumor effect of T cells, which recognize neoantigens as a cancer immunity target.

Since neoantigens are completely unique to every individual patient, this neoantigen-based approach involves individualized therapy. In other words, patients receive administration of personalized neoantigen vaccines tailored to each of them. Such personalized vaccination requires a development approach totally different from conventional mass-produced drugs intended for multiple patients in a predefined group.

  1. Analyzing tumors on an individual basis and producing a vaccine best for each patient
図2
  1. Flow of therapy with a fully-personalized neoantigen vaccine
図3
  1. Collect biopsy samples from the cancer patient
  2. Analyze collected samples through a next-generation DNA sequencer
  3. Identify cancer-specific mutations in the samples by leveraging bioinformatics
  4. Identify epitopes containing gene mutations, which are expected to be targeted by T cells
  5. Design peptides, and synthesize peptides to produce a vaccine

BP1209

  1. A new platform of personalized neoantigen cancer vaccines directed by checkpoint inhibitor antibodies to improve cancer immunity
図1

BP1209 is a proprietary, advanced cancer vaccine which targets tumor-specific neoantigens for the personalized treatment of cancer patients. The BP1209 vaccine is delivered as a molecular complex of patient-specific neoantigen peptides and immune-checkpoint inhibitor antibody such as anti-PD-L1 and anti-CD40 antibodies. The antibody directs the vaccine complex to dendritic cells (DCs), and enhances the cellular uptake of vaccine as well as the antigen-specific T cell priming by suppressing PD-1/PD-L1 signaling or CD40 activation.

The neoantigen peptides consists of three modules: HLA-class I and -class II neoantigen epitopes, and an IgG-binding motif. The peptides non-covalently bind Fc domain of IgG, and self-assemble the antibody-vaccine complex without any chemical reaction which enables individual synthesis and manufacturing fully personalized neoantigen vaccine. In this poster, authors demonstrate BP1209 strongly enhances antigen-specific immune responses and improves antitumor efficacy using cancer neoantigen. BrightPath has developed in-house bioinformatic algorithms to identify highly immunogenic neoantigens from cancer patients. The new vaccine platform of BP1209 in combination with BrightPath’s algorism to identify high quality neoantigens provides an ideal option to improve neoantigen vaccine therapy.

A new platform of personalized neoantigen cancer vaccines directed by checkpoint inhibitor antibodies to improve cancer immunity. ESMO 2021
VIEW POSTER

close